Future studies should validate these observations prospectively and evaluate whether contemporary therapies—such as SGLT2 inhibitors, renin–angiotensin system blockers, structured risk-factor modification, and optimized heart failure care—can translate into measurable improvements in both outcomes and daily well-being for patients with permanent AF, hypertension, and diabetes. This evidence concerns the gene SLC5A2 and Hypertension.